Anixa Biosciences Statistics
Share Statistics
Anixa Biosciences has 32.18M shares outstanding. The number of shares has increased by 3.57% in one year.
| Shares Outstanding | 32.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.54% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.55M |
| Failed to Deliver (FTD) Shares | 4.84K |
| FTD / Avg. Volume | 5.38% |
Short Selling Information
The latest short interest is 421.92K, so 1.31% of the outstanding shares have been sold short.
| Short Interest | 421.92K |
| Short % of Shares Out | 1.31% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 5.34 |
Valuation Ratios
The PE ratio is -9.98 and the forward PE ratio is -9.03.
| PE Ratio | -9.98 |
| Forward PE | -9.03 |
| PS Ratio | 466.18 |
| Forward PS | 0.8 |
| PB Ratio | 4.02 |
| P/FCF Ratio | -15.77 |
| PEG Ratio | n/a |
Enterprise Valuation
Anixa Biosciences Inc. has an Enterprise Value (EV) of 97.16M.
| EV / Earnings | -9.9 |
| EV / Sales | 462.65 |
| EV / EBITDA | -8.86 |
| EV / EBIT | -8.82 |
| EV / FCF | -15.65 |
Financial Position
The company has a current ratio of 12.5, with a Debt / Equity ratio of 0.
| Current Ratio | 12.5 |
| Quick Ratio | 12.5 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.4% and return on capital (ROIC) is -46.76%.
| Return on Equity (ROE) | -0.4% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -46.76% |
| Revenue Per Employee | 52.50K |
| Profits Per Employee | -2.45M |
| Employee Count | 4 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -24.27% in the last 52 weeks. The beta is 0.85, so Anixa Biosciences 's price volatility has been higher than the market average.
| Beta | 0.85 |
| 52-Week Price Change | -24.27% |
| 50-Day Moving Average | 3.21 |
| 200-Day Moving Average | 3.07 |
| Relative Strength Index (RSI) | 35.42 |
| Average Volume (20 Days) | 90.10K |
Income Statement
In the last 12 months, Anixa Biosciences had revenue of $210.00K and earned -$9.81M in profits. Earnings per share was $-0.32.
| Revenue | 210.00K |
| Gross Profit | 49.00K |
| Operating Income | -11.01M |
| Net Income | -9.81M |
| EBITDA | -10.96M |
| EBIT | -11.01M |
| Earnings Per Share (EPS) | -0.32 |
Balance Sheet
The company has $915.00K in cash and $175.00K in debt, giving a net cash position of $740.00K.
| Cash & Cash Equivalents | 915.00K |
| Total Debt | 175.00K |
| Net Cash | 740.00K |
| Retained Earnings | -228.20M |
| Total Assets | 22.91M |
| Working Capital | 20.67M |
Cash Flow
In the last 12 months, operating cash flow was -$6.21M and capital expenditures $0, giving a free cash flow of -$6.21M.
| Operating Cash Flow | -6.21M |
| Capital Expenditures | 0 |
| Free Cash Flow | -6.21M |
| FCF Per Share | -0.2 |
Margins
Gross margin is 23.33%, with operating and profit margins of -5.24K% and -4.67K%.
| Gross Margin | 23.33% |
| Operating Margin | -5.24K% |
| Pretax Margin | -4.73K% |
| Profit Margin | -4.67K% |
| EBITDA Margin | -5.22K% |
| EBIT Margin | -5.24K% |
| FCF Margin | -2.96K% |
Dividends & Yields
ANIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.27% |
| FCF Yield | -6.8% |
Analyst Forecast
The average price target for ANIX is $10, which is 252.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 252.1% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jun 26, 2015. It was a backward split with a ratio of 1:25.
| Last Split Date | Jun 26, 2015 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | 10.14 |
| Piotroski F-Score | 1 |